The N40D polymorphism in the human mu-opioid receptor (found in ~10% of people) severely impaired receptor signaling in response to beta-endorphin, potentially explaining individual differences in pain sensitivity and opioid drug response.
10% of people affectedThe N40D variant severely impairs natural opioid signaling — 1 in 10 people may have inherently weaker pain relief from their own endorphins
What the researchers found
The N40D polymorphism in the human mu-opioid receptor severely impaired beta-endorphin-stimulated G-protein coupling and downstream signaling, potentially explaining ~10% of the population's altered pain sensitivity and opioid drug response.
Why it matters
If 10% of people have a weakened natural painkilling receptor, this has massive implications for pain management, addiction risk, and personalized medicine — their endogenous opioid system is inherently less effective.
How the study worked
In-vitro study expressing wild-type and N40D variant mu-opioid receptors in cell lines. Receptor signaling (G-protein coupling, cAMP inhibition) measured in response to beta-endorphin and other opioid ligands.
What this study cannot tell us
In-vitro overexpression study may not perfectly represent in-vivo receptor function. The clinical consequences of the signaling impairment need population-level validation.
How to read the evidence
Moderate evidence from detailed in-vitro receptor pharmacology demonstrating clear functional consequences of a common genetic variant.
When this study was published
Published in 2001. The OPRM1 A118G/N40D polymorphism has become one of the most studied pharmacogenomic variants, with confirmed clinical associations.
The bigger picture
Pharmacogenomics — using genetic information to guide drug therapy — depends on identifying functional gene variants. This mu-opioid receptor polymorphism affects how the body's entire opioid system works, from pain perception to drug response to addiction risk.
Questions still open
- Do N40D carriers need different opioid doses for pain management?
- Does this variant increase addiction risk due to inadequate natural pain relief?
- Should mu-opioid receptor genotyping guide pain treatment?
Common questions
Why do some people feel more pain?
Should pain treatment be based on genetics?
Read the original research
A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling.
The Journal of biological chemistry, 276(5), 3130-7
Citation
Befort, K; Filliol, D; Decaillot, F M; Gaveriaux-Ruff, C; Hoehe, M R; Kieffer, B L. (2001). A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling.. The Journal of biological chemistry, 276(5), 3130-7.